Medicare's new GLP-1 Bridge program offers Wegovy and Zepbound for $50 a month. See who qualifies and how the pilot program works.
The Medicare GLP-1 Bridge is a temporary federal program that lets eligible Medicare beneficiaries pay just 50 dollars a month for certain GLP-1 weight loss drugs, including Wegovy and Zepbound, starting July 1 and running through the end of 2027.
At a Glance
- Flat 50 dollar monthly copay for covered GLP-1 drugs used for weight loss
- Pilot runs from July 1, 2025 through December 31, 2027
- Only three drug formulations currently qualify: Foundayo, Wegovy, and the Zepbound Kwikpen
- Eligibility depends on BMI thresholds combined with certain health conditions
- KFF estimates roughly 3.8 million beneficiaries could potentially qualify
Why Medicare Is Launching This Program
Medicare has historically refused to pay for drugs prescribed purely for weight loss. GLP-1 medications only qualified for coverage when doctors prescribed them for conditions like type 2 diabetes or cardiovascular disease. The Centers for Medicare and Medicaid Services is now testing a different approach through this demonstration program, aiming to widen access to these drugs for obesity management specifically.
Chris Klomp, who directs Medicare and serves as chief counselor at the Department of Health and Human Services, said the goal is to make getting these medications more predictable and consistent across the program. He framed the effort as one that could improve quality of life for seniors while also improving value across the broader health care system.
Which Drugs Qualify
The list of eligible medications is narrow for now. Three specific formulations make the cut:
- Foundayo, in tablet form
- Wegovy, available as either a tablet or injection
- Zepbound, specifically the Kwikpen version
Other GLP-1 products or formulations are not currently part of the program, so beneficiaries will need to confirm with their doctor and pharmacy that their specific prescription matches what qualifies.
What Beneficiaries Could Save
A flat 50 dollar monthly rate is a steep discount compared to what many people currently pay out of pocket for these drugs. On TrumpRx, the discount prescription platform launched by the Trump administration, a Wegovy tablet costs at least 149 dollars a month, and the Zepbound Kwikpen starts at 299 dollars. GoodRx lists Foundayo starting at 149 dollars monthly, with the Wegovy injection starting at 199 dollars. Those are just starting prices; costs climb further as patients move to higher doses or use different pharmacies.
| Scenario | Monthly Cost | 18 Month Total |
|---|---|---|
| Medicare GLP-1 Bridge | 50 dollars | about 900 dollars |
| Comparable market price | 200 dollars | about 3,600 dollars |
Under the Bridge program, the 50 dollar copay does not count toward a beneficiary's yearly Part D deductible or out of pocket limit. It also falls outside the Medicare Prescription Payment Plan and does not qualify for low income subsidies. Everyone pays the same flat rate regardless of income while the program runs.
Who Can Enroll
Anyone with Medicare Part D prescription drug coverage, whether through a standalone drug plan or a Medicare plan that bundles in Part D benefits, can potentially qualify, in any state or U.S. territory. But there are exclusions. Beneficiaries who already receive GLP-1 coverage for another qualifying condition, such as type 2 diabetes, sleep apnea, or fatty liver disease, are not eligible for the Bridge program and should keep receiving their medication through their existing coverage.
Bethose who don't already qualify through another condition, eligibility comes down to body mass index paired with specific health factors:- A BMI of 35 or higher on its own
- A BMI between 30 and 34.99 along with diastolic heart failure, hypertension, stage 3a or higher chronic kidney disease, prediabetes, a prior heart attack or stroke, or blocked arteries in the legs or arms
- A BMI between 27 and 29.99 along with prediabetes, a prior heart attack or stroke, or blocked arteries in the legs or arms
How to Get Started
The process begins with a doctor's prescription for one of the covered GLP-1 drugs, written specifically for weight loss or weight management. That prescription goes to a pharmacy, which may then request a prior authorization from the doctor to verify the patient meets the eligibility criteria above. Doctors and pharmacies do not need to sign up or opt into the program themselves.
Once approved, patients get single month refills at the same 50 dollar price, with the option to adjust dosage as needed, all the way through December 2027 when the program is scheduled to end.
Frequently Asked Questions
How many people qualify for the Medicare GLP-1 Bridge program?
Health policy research organization KFF estimates that around 3.8 million Medicare beneficiaries could be eligible based on 2023 data, though Medicare's own director has suggested a smaller, single digit million figure that could grow over time.
Does the 50 dollar copay count toward my deductible?
No. The program operates outside standard Medicare Part D coverage, so the flat copay does not apply toward yearly deductibles, out of pocket limits, or the Medicare Prescription Payment Plan.
Can I join if I already get GLP-1s through Medicare for diabetes?
No. Beneficiaries already receiving GLP-1 coverage for conditions such as type 2 diabetes, sleep apnea, or fatty liver disease are not eligible for the Bridge program and should continue with their current coverage.
When does the program end?
The Medicare GLP-1 Bridge is scheduled to run from July 1, 2025 through December 31, 2027, after which the demonstration will conclude unless Medicare decides otherwise.
What Comes Next
This is a demonstration program, not a permanent change to Medicare's drug coverage rules, so its long term future depends on how the pilot performs and what policymakers decide once it wraps up in 2027. For now, beneficiaries who think they might qualify have a real window to talk with their doctor about whether a covered GLP-1 makes sense for their situation.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified health care provider regarding any medical condition or treatment.
